• Conatumumab ELISA Kit
1 1

AntibodySystem

KDA29102

Conatumumab ELISA Kit

Conatumumab ELISA Kit

Title

Catalog No.: KDA29102

Catalog No. KDA29102
Product name Conatumumab ELISA Kit
Size 96 T
Description PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD262 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Conatumumab in the sample competitively binds to the pre-coated protein with biotin-labeled Conatumumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Conatumumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications Used for the quantitative determination of Conatumumab concentration in serum and plasma.
Stability and Storage When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Detection method Colorimetric
Precision CV<20%
Sample type Plasma, Serum
Assay type Quantitative
Sensitivity 91.95 ng/mL
Range 78.13 - 5,000 ng/mL
Recovery 80-120%
Background Conatumumab (previously called AMG-655) is a fully human Immunoglobulin G1 (IgG1) type monoclonal binding to tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) which could induce apoptosis in many types of human cancer cells. This drug was developed by Amgen Inc and Japanese licensee Takeda Bio Development Center Ltd with potential antineoplastic activity. This drug has been investigated in trials studying the treatment of sarcoma, lymphoma, oncology, colon cancer, and rectal cancer. Conatumumab can elicit the apoptosis in cell lines derived from colon and pancreatic cancers, as well as in mice bearing xenograft tumors in some in vitro and in vivo assays. Clinical trials in phase I has assessed the safety of conatumumab as a monotherapy as well as in combination with other antibody therapies or standard chemotherapeutic regimes. And the anti-conatumumab antibody responses have not been observed in previous trials. In addition, conatumumab has been found to enhance the antitumor activity of agents like irinotecan and gemcitabine in some preclinical researches. A trail about conatumumab combined with AMG 479 has shown that it is well-tolerated and no drug-drug interactions and the phase II development of this combination is ongoing.
Alternative Names AMG 655, TRAIL-R2mAb, XG1-048 v w, CAS: 896731-82-1
Shipping 2-8 ℃
Note For Research Use Only.
전체 세부 정보 보기